{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:37:01Z","timestamp":1791927421511,"version":"4.3.4"},"reference-count":157,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Faculty of Medical Sciences, University of Kragujevac","award":["JP 27\/20"],"award-info":[{"award-number":["JP 27\/20"]}]},{"name":"Faculty of Medical Sciences, University of Kragujevac","award":["451-03-47\/2023-01\/200111"],"award-info":[{"award-number":["451-03-47\/2023-01\/200111"]}]},{"name":"Faculty of Medical Sciences, University of Kragujevac","award":["451-03-66\/2024-03\/200110"],"award-info":[{"award-number":["451-03-66\/2024-03\/200110"]}]},{"name":"Faculty of Medical Sciences, University of Kragujevac","award":["451-03-65\/2024-03\/200161"],"award-info":[{"award-number":["451-03-65\/2024-03\/200161"]}]},{"name":"Faculty of Medical Sciences, University of Kragujevac","award":["451-03-66\/2024-03\/200161"],"award-info":[{"award-number":["451-03-66\/2024-03\/200161"]}]},{"name":"the Ministry of Science, Technical Development, and Innovation of the Republic of Serbia","award":["JP 27\/20"],"award-info":[{"award-number":["JP 27\/20"]}]},{"name":"the Ministry of Science, Technical Development, and Innovation of the Republic of Serbia","award":["451-03-47\/2023-01\/200111"],"award-info":[{"award-number":["451-03-47\/2023-01\/200111"]}]},{"name":"the Ministry of Science, Technical Development, and Innovation of the Republic of Serbia","award":["451-03-66\/2024-03\/200110"],"award-info":[{"award-number":["451-03-66\/2024-03\/200110"]}]},{"name":"the Ministry of Science, Technical Development, and Innovation of the Republic of Serbia","award":["451-03-65\/2024-03\/200161"],"award-info":[{"award-number":["451-03-65\/2024-03\/200161"]}]},{"name":"the Ministry of Science, Technical Development, and Innovation of the Republic of Serbia","award":["451-03-66\/2024-03\/200161"],"award-info":[{"award-number":["451-03-66\/2024-03\/200161"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antioxidants"],"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), encompasses a range of liver conditions from steatosis to nonalcoholic steatohepatitis (NASH). Its prevalence, especially among patients with metabolic syndrome, highlights its growing global impact. The pathogenesis of MASLD involves metabolic dysregulation, inflammation, oxidative stress, genetic factors and, notably, mitochondrial dysfunction. Recent studies underscore the critical role of mitochondrial dysfunction in MASLD\u2019s progression. Therapeutically, enhancing mitochondrial function has gained interest, along with lifestyle changes and pharmacological interventions targeting mitochondrial processes. The FDA\u2019s approval of resmetirom for metabolic-associated steatohepatitis (MASH) with fibrosis marks a significant step. While resmetirom represents progress, further research is essential to understand MASLD-related mitochondrial dysfunction fully. Innovative strategies like gene editing and small-molecule modulators, alongside lifestyle interventions, can potentially improve MASLD treatment. Drug repurposing and new targets will advance MASLD therapy, addressing its increasing global burden. Therefore, this review aims to provide a better understanding of the role of mitochondrial dysfunction in MASLD and identify more effective preventive and treatment strategies.<\/jats:p>","DOI":"10.3390\/antiox13080906","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T14:39:08Z","timestamp":1722004748000},"page":"906","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["Altered Mitochondrial Function in MASLD: Key Features and Promising Therapeutic Approaches"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1701-3313","authenticated-orcid":false,"given":"Tatjana","family":"Radosavljevic","sequence":"first","affiliation":[{"name":"Institute of Pathophysiology \u201cLjubodrag Buba Mihailovic\u201d, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milica","family":"Brankovic","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8464-4924","authenticated-orcid":false,"given":"Janko","family":"Samardzic","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8457-4962","authenticated-orcid":false,"given":"Jasmina","family":"Djureti\u0107","sequence":"additional","affiliation":[{"name":"Department of Pathobiology, Faculty of Pharmacy, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dusan","family":"Vukicevic","sequence":"additional","affiliation":[{"name":"Uniklinik Mannheim, Theodor-Kutyer-Ufer 1-3, 68167 Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danijela","family":"Vucevic","sequence":"additional","affiliation":[{"name":"Institute of Pathophysiology \u201cLjubodrag Buba Mihailovic\u201d, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Jakovljevic","sequence":"additional","affiliation":[{"name":"Department of Physiology, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovica 69, 34000 Kragujevac, Serbia"},{"name":"Center of Excellence for the Study of Redox Balance in Cardiovascular and Metabolic Disorders, University of Kragujevac, Svetozara Markovica 69, 34000 Kragujevac, Serbia"},{"name":"Department of Human Pathology, First Moscow State Medical University I.M. Sechenov, Trubetskaya Street 8, Str. 2, 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Phoolchund, A.G.S., and Khakoo, S.I. (2024). MASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges. Cancers, 16.","DOI":"10.3390\/cancers16020259"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A Multisociety Delphi Consensus Statement on New Fatty Liver Disease Nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Alabdul Razzak, I., Noureddin, M., and Trivedi, H. (2024). From Nonalcoholic Fatty Liver Disease to Metabolic Dysfunction-Associated Steatotic Liver Disease: Out with the Old, in with the New. J. Clin. Med., 13.","DOI":"10.3390\/jcm13030880"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejim.2023.11.012","article-title":"Management of Cardiovascular Risk in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"122","author":"Haldrup","year":"2024","journal-title":"Eur. J. Intern. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"204201882211455","DOI":"10.1177\/20420188221145549","article-title":"MAFLD: A Multisystem Disease","volume":"14","author":"Pipitone","year":"2023","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Lazarus, J.V., Ivancovsky Wajcman, D., Mark, H.E., Younossi, Z.M., Kopka, C.J., Cohen, N., Bansal, M.B., Betel, M., and Brennan, P.N. (2024). Opportunities and Challenges Following Approval of Resmetirom for MASH Liver Disease. Nat. Med., 1\u20134.","DOI":"10.1038\/s41591-024-02958-z"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Yang, K., and Song, M. (2023). New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut\u2013Liver\u2013Heart Crosstalk. Nutrients, 15.","DOI":"10.3390\/nu15183970"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"289","DOI":"10.7570\/jomes23054","article-title":"Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","volume":"32","author":"Shin","year":"2023","journal-title":"J. Obes. Metab. Syndr."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Arumugam, M.K., Gopal, T., Kalari Kandy, R.R., Boopathy, L.K., Perumal, S.K., Ganesan, M., Rasineni, K., Donohue, T.M., Osna, N.A., and Kharbanda, K.K. (2023). Mitochondrial Dysfunction-Associated Mechanisms in the Development of Chronic Liver Diseases. Biology, 12.","DOI":"10.3390\/biology12101311"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Caputo, V., Tarantino, G., Santini, S.J., Fracassi, G., and Balsano, C. (2023). The Role of Epigenetic Control of Mitochondrial (Dys)Function in MASLD Onset and Progression. Nutrients, 15.","DOI":"10.3390\/nu15224757"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Casanova, A., Wevers, A., Navarro-Ledesma, S., and Pruimboom, L. (2023). Mitochondria: It Is All about Energy. Front. Physiol., 14.","DOI":"10.3389\/fphys.2023.1114231"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Tang, J.X., Thompson, K., Taylor, R.W., and Ol\u00e1hov\u00e1, M. (2020). Mitochondrial OXPHOS Biogenesis: Co-Regulation of Protein Synthesis, Import, and Assembly Pathways. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21113820"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41392-023-01547-9","article-title":"Mitochondrial Dynamics in Health and Disease: Mechanisms and Potential Targets","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Kowalczyk, P., Sulejczak, D., Kleczkowska, P., Bukowska-O\u015bko, I., Kucia, M., Popiel, M., Wietrak, E., Kramkowski, K., Wrzosek, K., and Kaczy\u0144ska, K. (2021). Mitochondrial Oxidative Stress-A Causative Factor and Therapeutic Target in Many Diseases. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222413384"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1007\/s00204-023-03562-9","article-title":"Reactive Oxygen Species, Toxicity, Oxidative Stress, and Antioxidants: Chronic Diseases and Aging","volume":"97","author":"Jomova","year":"2023","journal-title":"Arch. Toxicol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejphar.2019.01.043","article-title":"Betaine Modulates Oxidative Stress, Inflammation, Apoptosis, Autophagy, and Akt\/mTOR Signaling in Methionine-Choline Deficiency-Induced Fatty Liver Disease","volume":"848","author":"Veskovic","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"8900122","DOI":"10.1155\/2021\/8900122","article-title":"Mitochondrial Mechanisms of Apoptosis and Necroptosis in Liver Diseases","volume":"2021","author":"Chu","year":"2021","journal-title":"Anal. Cell. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/0192623312466961","article-title":"Molecular Mechanisms That Differentiate Apoptosis from Programmed Necrosis","volume":"41","author":"Dorn","year":"2013","journal-title":"Toxicol. Pathol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6617256","DOI":"10.1155\/2021\/6617256","article-title":"The Role of Mitophagy in Regulating Cell Death","volume":"2021","author":"Li","year":"2021","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Doblado, L., Lueck, C., Rey, C., Samhan-Arias, A.K., Prieto, I., Stacchiotti, A., and Monsalve, M. (2021). Mitophagy in Human Diseases. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22083903"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Atici, A.E., Crother, T.R., and Noval Rivas, M. (2023). Mitochondrial Quality Control in Health and Cardiovascular Diseases. Front. Cell Dev. Biol., 11.","DOI":"10.3389\/fcell.2023.1290046"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4892","DOI":"10.1111\/jcmm.15194","article-title":"Mitochondrial Biogenesis: An Update","volume":"24","author":"Popov","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Ding, Q., Qi, Y., and Tsang, S.-Y. (2021). Mitochondrial Biogenesis, Mitochondrial Dynamics, and Mitophagy in the Maturation of Cardiomyocytes. Cells, 10.","DOI":"10.3390\/cells10092463"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Zhao, F., and Zou, M.-H. (2021). Role of the Mitochondrial Protein Import Machinery and Protein Processing in Heart Disease. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.749756"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Green, A., Hossain, T., and Eckmann, D.M. (2022). Mitochondrial Dynamics Involves Molecular and Mechanical Events in Motility, Fusion and Fission. Front. Cell Dev. Biol., 10.","DOI":"10.3389\/fcell.2022.1010232"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Wang, S., Tan, J., Miao, Y., and Zhang, Q. (2022). Mitochondrial Dynamics, Mitophagy, and Mitochondria\u2013Endoplasmic Reticulum Contact Sites Crosstalk Under Hypoxia. Front. Cell Dev. Biol., 10.","DOI":"10.3389\/fcell.2022.848214"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.tcb.2020.09.008","article-title":"Mitochondrial Fusion: The Machineries in and Out","volume":"31","author":"Gao","year":"2021","journal-title":"Trends Cell Biol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Zerihun, M., Sukumaran, S., and Qvit, N. (2023). The Drp1-Mediated Mitochondrial Fission Protein Interactome as an Emerging Core Player in Mitochondrial Dynamics and Cardiovascular Disease Therapy. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065785"},{"key":"ref_29","first-page":"1","article-title":"Recent Insights into the Mitochondrial Role in Autophagy and Its Regulation by Oxidative Stress","volume":"2019","author":"Morales","year":"2019","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/s41392-023-01503-7","article-title":"The Mitophagy Pathway and Its Implications in Human Diseases","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1172\/JCI83885","article-title":"Hepatocyte Mitochondrial DNA Drives Nonalcoholic Steatohepatitis by Activation of TLR9","volume":"126","author":"Santoro","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e13622","DOI":"10.1111\/eci.13622","article-title":"Mitochondria, Oxidative Stress and Nonalcoholic Fatty Liver Disease: A Complex Relationship","volume":"52","author":"Simoes","year":"2022","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Ore, A., and Akinloye, O. (2019). Oxidative Stress and Antioxidant Biomarkers in Clinical and Experimental Models of Non-Alcoholic Fatty Liver Disease. Medicina, 55.","DOI":"10.3390\/medicina55020026"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Ma, Y., Lee, G., Heo, S.-Y., and Roh, Y.-S. (2021). Oxidative Stress Is a Key Modulator in the Development of Nonalcoholic Fatty Liver Disease. Antioxidants, 11.","DOI":"10.3390\/antiox11010091"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s13679-022-00473-1","article-title":"Hepatocyte Mitochondrial Dynamics and Bioenergetics in Obesity-Related Non-Alcoholic Fatty Liver Disease","volume":"11","author":"Legaki","year":"2022","journal-title":"Curr. Obes. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6626484","DOI":"10.1155\/2021\/6626484","article-title":"Targeting the Mitochondrial Permeability Transition Pore to Prevent Age-Associated Cell Damage and Neurodegeneration","volume":"2021","author":"Kent","year":"2021","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13045-023-01512-7","article-title":"Reactive Oxygen Species (ROS) Scavenging Biomaterials for Anti-Inflammatory Diseases: From Mechanism to Therapy","volume":"16","author":"Liu","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/iid3.391","article-title":"Inflammation Initiates a Vicious Cycle between Obesity and Nonalcoholic Fatty Liver Disease","volume":"9","author":"Luo","year":"2021","journal-title":"Immun. Inflamm. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3164\/jcbn.22-73","article-title":"High-Fat Diet Causes Mitochondrial Damage and Downregulation of Mitofusin-2 and Optic Atrophy-1 in Multiple Organs","volume":"73","author":"Zheng","year":"2023","journal-title":"J. Clin. Biochem. Nutr."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.bbrc.2019.04.069","article-title":"IDH2 Protects against Nonalcoholic Steatohepatitis by Alleviating Dyslipidemia Regulated by Oxidative Stress","volume":"514","author":"Gong","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.cell.2019.04.010","article-title":"Deficient Endoplasmic Reticulum-Mitochondrial Phosphatidylserine Transfer Causes Liver Disease","volume":"177","author":"Vives","year":"2019","journal-title":"Cell"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1152\/ajpregu.00437.2010","article-title":"Regulation of Mitochondrial Morphology and Function by O-GlcNAcylation in Neonatal Cardiac Myocytes","volume":"300","author":"Makino","year":"2011","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez, A.G., Rodr\u00edguez, J.Z., Barreto, A., Sanabria-Barrera, S., Iglesias, J., and Morales, L. (2023). Impact of Acute High Glucose on Mitochondrial Function in a Model of Endothelial Cells: Role of PDGF-C. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054394"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.cmet.2015.04.016","article-title":"Opa1 Overexpression Ameliorates the Phenotype of Two Mitochondrial Disease Mouse Models","volume":"21","author":"Civiletto","year":"2015","journal-title":"Cell Metab."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.cmet.2015.05.007","article-title":"The Opa1-Dependent Mitochondrial Cristae Remodeling Pathway Controls Atrophic, Apoptotic, and Ischemic Tissue Damage","volume":"21","author":"Varanita","year":"2015","journal-title":"Cell Metab."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"103996","DOI":"10.1016\/j.isci.2022.103996","article-title":"Prevention and Regression of Megamitochondria and Steatosis by Blocking Mitochondrial Fusion in the Liver","volume":"25","author":"Yamada","year":"2022","journal-title":"iScience"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"6721","DOI":"10.1038\/s41467-023-42564-0","article-title":"The Mitochondrial Fusion Protein OPA1 Is Dispensable in the Liver and Its Absence Induces Mitohormesis to Protect Liver from Drug-Induced Injury","volume":"14","author":"Lee","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1093\/cvr\/cvad169","article-title":"The Inhibition of Inner Mitochondrial Fusion in Hepatocytes Reduces Non-Alcoholic Fatty Liver and Improves Metabolic Profile during Obesity by Modulating Bile Acid Conjugation","volume":"119","author":"Moregola","year":"2024","journal-title":"Cardiovasc. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.2337\/db23-1599-P","article-title":"Regulation of Mitochondrial Dynamics Ameliorates Hepatic Steatosis through TFEB Activation","volume":"72","author":"Yoo","year":"2023","journal-title":"Diabetes"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s42255-024-00978-0","article-title":"Obesity Causes Mitochondrial Fragmentation and Dysfunction in White Adipocytes due to RalA Activation","volume":"6","author":"Xia","year":"2024","journal-title":"Nat. Metab."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1152\/ajpgi.00182.2014","article-title":"Decreasing Mitochondrial Fission Alleviates Hepatic Steatosis in a Murine Model of Nonalcoholic Fatty Liver Disease","volume":"307","author":"Galloway","year":"2014","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Zhou, T., Chang, L., Luo, Y., Zhou, Y., and Zhang, J. (2019). Mst1 Inhibition Attenuates Non-Alcoholic Fatty Liver Disease via Reversing Parkin-Related Mitophagy. Redox Biol., 21.","DOI":"10.1016\/j.redox.2019.101120"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"7575","DOI":"10.1038\/s41598-023-34710-x","article-title":"Reduced Mitophagy Is an Early Feature of NAFLD and Liver-Specific PARKIN Knockout Hastens the Onset of Steatosis, Inflammation and Fibrosis","volume":"13","author":"Undamatla","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1128\/MCB.00167-12","article-title":"BNip3 Regulates Mitochondrial Function and Lipid Metabolism in the Liver","volume":"32","author":"Glick","year":"2012","journal-title":"Mol. Cell. Biol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Kyriakoudi, S., Drousiotou, A., and Petrou, P.P. (2021). When the Balance Tips: Dysregulation of Mitochondrial Dynamics as a Culprit in Disease. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094617"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mito.2017.10.009","article-title":"Mitophagy and the Release of Inflammatory Cytokines","volume":"41","author":"Harris","year":"2018","journal-title":"Mitochondrion"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e13464","DOI":"10.1111\/obr.13464","article-title":"The Effect of Pharmacological Treatment and Lifestyle Modification in Patients with Nonalcoholic Fatty Liver Disease: An Umbrella Review of Meta-analyses of Randomized Controlled Trials","volume":"23","author":"Cho","year":"2022","journal-title":"Obes. Rev."},{"key":"ref_58","unstructured":"(2024, April 13). FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease. U.S. Food and Drug Administration, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_60","first-page":"60","article-title":"Resmetirom: An Orally Administered, Small-Molecule, Liver-Directed, \u03b2-Selective THR Agonist for the Treatment of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis","volume":"19","author":"Karim","year":"2023","journal-title":"Eur. Endocrinol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12944-024-02092-2","article-title":"Advances in Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Mechanisms to Therapeutics","volume":"23","author":"Jiang","year":"2024","journal-title":"Lipids Health Dis."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Heinle, J.W., DiJoseph, K., Sabag, A., Oh, S., Kimball, S.R., Keating, S., and Stine, J.G. (2023). Exercise Is Medicine for Nonalcoholic Fatty Liver Disease: Exploration of Putative Mechanisms. Nutrients, 15.","DOI":"10.3390\/nu15112452"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1080\/17461391.2019.1571114","article-title":"Mechanisms of Beneficial Effects of Exercise Training on Non-alcoholic Fatty Liver Disease (NAFLD): Roles of Oxidative Stress and Inflammation","volume":"19","author":"Farzanegi","year":"2019","journal-title":"Eur. J. Sport Sci."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Docherty, S., Harley, R., McAuley, J.J., Crowe, L.A.N., Pedret, C., Kirwan, P.D., Siebert, S., and Millar, N.L. (2022). The Effect of Exercise on Cytokines: Implications for Musculoskeletal Health: A Narrative Review. BMC Sports Sci. Med. Rehabil., 14.","DOI":"10.1186\/s13102-022-00397-2"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Zhu, W., Sahar, N.E., Javaid, H.M.A., Pak, E.S., Liang, G., Wang, Y., Ha, H., and Huh, J.Y. (2021). Exercise-Induced Irisin Decreases Inflammation and Improves NAFLD by Competitive Binding with MD2. Cells, 10.","DOI":"10.3390\/cells10123306"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Kawamura, T., and Muraoka, I. (2018). Exercise-Induced Oxidative Stress and the Effects of Antioxidant Intake from a Physiological Viewpoint. Antioxidants, 7.","DOI":"10.3390\/antiox7090119"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Zou, Y.-Y., Tang, X.-B., Chen, Z.-L., Liu, B., Zheng, L., Song, M.-Y., Xiao, Q., Zhou, Z.-Q., Peng, X.-Y., and Tang, C.-F. (2023). Exercise Intervention Improves Mitochondrial Quality in Non-Alcoholic Fatty Liver Disease Zebrafish. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1162485"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Clemente-Su\u00e1rez, V.J., Beltr\u00e1n-Velasco, A.I., Redondo-Fl\u00f3rez, L., Mart\u00edn-Rodr\u00edguez, A., and Tornero-Aguilera, J.F. (2023). Global Impacts of Western Diet and Its Effects on Metabolism and Health: A Narrative Review. Nutrients, 15.","DOI":"10.3390\/nu15122749"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3390\/diabetology3040044","article-title":"The Bitter Side of Sugar Consumption: A Mitochondrial Perspective on Diabetes Development","volume":"3","author":"Diniz","year":"2022","journal-title":"Diabetology"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Miryan, M., Darbandi, M., Moradi, M., Najafi, F., Soleimani, D., and Pasdar, Y. (2023). Relationship between the Mediterranean Diet and Risk of Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Analysis of the RaNCD. Cohort. Front. Nutr., 10.","DOI":"10.3389\/fnut.2023.1062008"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/bcp.12986","article-title":"Polyphenol Intake from a Mediterranean Diet Decreases Inflammatory Biomarkers Related to Atherosclerosis: A Substudy of the PREDIMED Trial","volume":"83","author":"Casas","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Krawczyk, M., Burzynska-Pedziwiatr, I., Wozniak, L.A., and Bukowiecka-Matusiak, M. (2023). Impact of Polyphenols on Inflammatory and Oxidative Stress Factors in Diabetes Mellitus: Nutritional Antioxidants and Their Application in Improving Antidiabetic Therapy. Biomolecules, 13.","DOI":"10.3390\/biom13091402"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.abb.2014.05.017","article-title":"Polyphenols and Mitochondria: An Update on Their Increasingly Emerging ROS-Scavenging Independent Actions","volume":"559","author":"Ferreira","year":"2014","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Xu, J., Shen, J., Yuan, R., Jia, B., Zhang, Y., Wang, S., Zhang, Y., Liu, M., and Wang, T. (2021). Mitochondrial Targeting Therapeutics: Promising Role of Natural Products in Non-Alcoholic Fatty Liver Disease. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.796207"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1007\/s12035-018-1368-2","article-title":"Bezafibrate Upregulates Mitochondrial Biogenesis and Influence Neural Differentiation of Human-Induced Pluripotent Stem Cells","volume":"56","author":"Augustyniak","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41387-020-00130-3","article-title":"Neohesperidin Enhances PGC-1\u03b1-Mediated Mitochondrial Biogenesis and Alleviates Hepatic Steatosis in High Fat Diet Fed Mice","volume":"10","author":"Wang","year":"2020","journal-title":"Nutr. Diabetes"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Dong, Y., Yu, M., Wu, Y., Xia, T., Wang, L., Song, K., Zhang, C., Lu, K., and Rahimnejad, S. (2022). Hydroxytyrosol Promotes the Mitochondrial Function through Activating Mitophagy. Antioxidants, 11.","DOI":"10.3390\/antiox11050893"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.mito.2013.09.002","article-title":"Berberine Reverts Hepatic Mitochondrial Dysfunction in High-Fat Fed Rats: A Possible Role for SirT3 Activation","volume":"13","author":"Teodoro","year":"2013","journal-title":"Mitochondrion"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2023\/7277060","article-title":"A Comprehensive Insight into the Effect of Berberine on Nonalcoholic Fatty Liver Disease (NAFLD): A Systematic Review","volume":"2023","author":"Karimi","year":"2023","journal-title":"J. Food Biochem."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Wang, Y., Tai, Y.-L., Zhao, D., Zhang, Y., Yan, J., Kakiyama, G., Wang, X., Gurley, E.C., Liu, J., and Liu, J. (2021). Berberine Prevents Disease Progression of Nonalcoholic Steatohepatitis through Modulating Multiple Pathways. Cells, 10.","DOI":"10.3390\/cells10020210"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12967-024-05011-2","article-title":"The Clinical Efficacy and Safety of Berberine in the Treatment of Non-Alcoholic Fatty Liver Disease: A Meta-Analysis and Systematic Review","volume":"22","author":"Nie","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.nut.2005.12.014","article-title":"Effects of Dietary Genistein on Hepatic Lipid Metabolism and Mitochondrial Function in Mice Fed High-Fat Diets","volume":"22","author":"Lee","year":"2006","journal-title":"Nutrition"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Seidemann, L., Kr\u00fcger, A., Kegel-H\u00fcbner, V., Seehofer, D., and Damm, G. (2021). Influence of Genistein on Hepatic Lipid Metabolism in an In Vitro Model of Hepatic Steatosis. Molecules, 26.","DOI":"10.3390\/molecules26041156"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"101174","DOI":"10.1016\/j.aohep.2023.101174","article-title":"Administration of Silymarin in NAFLD\/NASH: A Systematic Review and Meta-Analysis","volume":"29","author":"Li","year":"2024","journal-title":"Ann. Hepatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1124\/jpet.109.161612","article-title":"A Silybin-Phospholipid Complex Prevents Mitochondrial Dysfunction in a Rodent Model of Nonalcoholic Steatohepatitis","volume":"332","author":"Serviddio","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Berumen, C.I., Vargas-Vargas, M.A., Ortiz-Avila, O., Pi\u00f1a-Zentella, R.M., Ramos-G\u00f3mez, M., Figueroa-Garc\u00eda, M.d.C., Mej\u00eda-Zepeda, R., Rodr\u00edguez-Orozco, A.R., Saavedra-Molina, A., and Cort\u00e9s-Rojo, C. (2022). Avocado Oil Alleviates Non-Alcoholic Fatty Liver Disease by Improving Mitochondrial Function, Oxidative Stress and Inflammation in Rats Fed a High Fat\u2013High Fructose Diet. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1089130"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"121943","DOI":"10.1016\/j.lfs.2023.121943","article-title":"The Emerging Significance of Mitochondrial Targeted Strategies in NAFLD Treatment","volume":"329","author":"Zhang","year":"2023","journal-title":"Life Sci."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"100037","DOI":"10.1016\/j.arres.2022.100037","article-title":"Pharmacological Significance of MitoQ in Ameliorating Mitochondria-Related Diseases","volume":"5","author":"Sulaimon","year":"2022","journal-title":"Adv. Redox Res."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Williamson, J., Hughes, C.M., Cobley, J.N., and Davison, G.W. (2020). The Mitochondria-Targeted Antioxidant MitoQ, Attenuates Exercise-Induced Mitochondrial DNA Damage. Redox Biol., 36.","DOI":"10.1016\/j.redox.2020.101673"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41698-024-00536-7","article-title":"Selpercatinib Combination with the Mitochondria-Targeted Antioxidant MitoQ Effectively Suppresses RET\u2013Mutant Thyroid Cancer","volume":"8","author":"Chen","year":"2024","journal-title":"NPJ Precis. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cryobiol.2022.12.019","article-title":"Protective Effects of Different Doses of MitoQ Separately and Combined with Trehalose on Oxidative Stress and Sperm Function of Cryopreserved Markhoz Goat Semen","volume":"110","author":"Rezaei","year":"2023","journal-title":"Cryobiology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e28158","DOI":"10.1016\/j.heliyon.2024.e28158","article-title":"Cardioprotective Effect of Antioxidant Combination Therapy: A Highlight on MitoQ plus Alpha-Lipoic Acid Beneficial Impact on Myocardial Ischemia-Reperfusion Injury in Aged Rats","volume":"10","author":"Oskuye","year":"2024","journal-title":"Heliyon"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jacbts.2018.12.005","article-title":"Elamipretide Improves Mitochondrial Function in the Failing Human Heart","volume":"4","author":"Chatfield","year":"2019","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Allen, M.E., Pennington, E.R., Perry, J.B., Dadoo, S., Makrecka-Kuka, M., Dambrova, M., Moukdar, F., Patel, H.D., Han, X., and Kidd, G.K. (2020). The Cardiolipin-Binding Peptide Elamipretide Mitigates Fragmentation of Cristae Networks Following Cardiac Ischemia Reperfusion in Rats. Commun. Biol., 3.","DOI":"10.1038\/s42003-020-1101-3"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1007\/s11357-023-00861-y","article-title":"The Mitochondrially Targeted Peptide Elamipretide (SS-31) Improves ADP Sensitivity in Aged Mitochondria by Increasing Uptake through the Adenine Nucleotide Translocator (ANT)","volume":"45","author":"Pharaoh","year":"2023","journal-title":"GeroScience"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.mito.2021.03.001","article-title":"Mitochondria-Targeted Antioxidant, Mito-TEMPO Mitigates Initiation Phase of N-Nitrosodiethylamine-Induced Hepatocarcinogenesis","volume":"58","author":"Shetty","year":"2021","journal-title":"Mitochondrion"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"6394199","DOI":"10.1155\/2022\/6394199","article-title":"Hepatoprotective Effect of Mitochondria-Targeted Antioxidant Mito-TEMPO against Lipopolysaccharide-Induced Liver Injury in Mouse","volume":"2022","author":"Wang","year":"2022","journal-title":"Mediat. Inflamm."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Chen, J.-W., Ma, P.-W., Yuan, H., Wang, W.-L., Lu, P.-H., Ding, X.-R., Lun, Y.-Q., Yang, Q., and Lu, L.-J. (2022). Mito-TEMPO Attenuates Oxidative Stress and Mitochondrial Dysfunction in Noise-Induced Hearing Loss via Maintaining TFAM-mtDNA Interaction and Mitochondrial Biogenesis. Front. Cell. Neurosci., 16.","DOI":"10.3389\/fncel.2022.803718"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1475-2891-13-17","article-title":"Peroxisome Proliferator-Activated Receptors and Their Ligands: Nutritional and Clinical Implications\u2014A Review","volume":"13","year":"2014","journal-title":"Nutr. J."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular Mechanism of PPAR\u03b1 Action and Its Impact on Lipid Metabolism, Inflammation and Fibrosis in Non-Alcoholic Fatty Liver Disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/CIRCRESAHA.109.206185","article-title":"Peroxisome Proliferator-Activated Receptor \u03b4 Is an Essential Transcriptional Regulator for Mitochondrial Protection and Biogenesis in Adult Heart","volume":"106","author":"Wang","year":"2010","journal-title":"Circ. Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.freeradbiomed.2016.06.023","article-title":"PPAR\u03b3 as a Therapeutic Target to Rescue Mitochondrial Function in Neurological Disease","volume":"100","author":"Corona","year":"2016","journal-title":"Free Radic. Biol. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2306185","article-title":"Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis","volume":"390","author":"Kowdley","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Zhang, M., Barroso, E., Ruart, M., Pe\u00f1a, L., Peyman, M., Aguilar-Recarte, D., Montori-Grau, M., Rada, P., Cugat, C., and Montironi, C. (2023). Elafibranor Upregulates the EMT-Inducer S100A4 via PPAR\u03b2\/\u03b4. Biomed. Pharmacother., 167.","DOI":"10.1016\/j.biopha.2023.115623"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/13543784.2020.1668375","article-title":"Elafibranor: A Potential Drug for the Treatment of Nonalcoholic Steatohepatitis (NASH)","volume":"29","author":"Drenth","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.phrs.2019.04.016","article-title":"Elafibranor Restricts Lipogenic and Inflammatory Responses in a Human Skin Stem Cell-Derived Model of NASH","volume":"144","author":"Boeckmans","year":"2019","journal-title":"Pharmacol. Res."},{"key":"ref_107","unstructured":"(2024, April 17). RESOLVE-IT Phase 3 of Elafibranor in NASH: Final Results of the Week 72 Interim Surrogate Efficacy Analysis. Natap.org. Available online: https:\/\/www.natap.org\/2020\/AASLD\/AASLD_162.htm."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11892-019-1270-y","article-title":"Thiazolidinediones: The Forgotten Diabetes Medications","volume":"19","author":"Lebovitz","year":"2019","journal-title":"Curr. Diab. Rep."},{"key":"ref_109","first-page":"e25380","article-title":"The Role of Thiazolidinediones in the Amelioration of Nonalcoholic Fatty Liver Disease: A Systematic Review","volume":"14","author":"Ndakotsu","year":"2022","journal-title":"Cureus"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2337\/dsi23-0012","article-title":"Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies","volume":"37","author":"Genua","year":"2024","journal-title":"Diabetes Spectr."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.bbrc.2008.11.141","article-title":"TZDs Reduce Mitochondrial ROS Production and Enhance Mitochondrial Biogenesis","volume":"379","author":"Fujisawa","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Skov, V., Glintborg, D., Knudsen, S., Tan, Q., Jensen, T., Kruse, T.A., Beck-Nielsen, H., and H\u00f8jlund, K. (2008). Pioglitazone Enhances Mitochondrial Biogenesis and Ribosomal Protein Biosynthesis in Skeletal Muscle in Polycystic Ovary Syndrome. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0002466"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1152\/ajpendo.00023.2018","article-title":"Pioglitazone Improves Hepatic Mitochondrial Function in a Mouse Model of Nonalcoholic Steatohepatitis","volume":"315","author":"Kalavalapalli","year":"2018","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Hodges, W.T., Jarasvaraparn, C., Ferguson, D., Griffett, K., Gill, L.E., Chen, Y., Ilagan, M.X.G., Hegazy, L., Elgendy, B., and Cho, K. (2022). Mitochondrial Pyruvate Carrier Inhibitors Improve Metabolic Parameters in Diet-Induced Obese Mice. J. Biol. Chem., 298.","DOI":"10.1016\/j.jbc.2021.101554"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Kamm, D.R., Pyles, K.D., Sharpe, M.C., Healy, L.N., Colca, J.R., and McCommis, K.S. (2021). Novel Insulin Sensitizer MSDC-0602K Improves Insulinemia and Fatty Liver Disease in Mice, Alone and in Combination with Liraglutide. J. Biol. Chem., 296.","DOI":"10.1016\/j.jbc.2021.100807"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"101598","DOI":"10.1016\/j.molmet.2022.101598","article-title":"Novel Thiazolidinedione Analog Reduces a Negative Impact on Bone and Mesenchymal Stem Cell Properties in Obese Mice Compared to Classical Thiazolidinediones","volume":"65","author":"Benova","year":"2022","journal-title":"Mol. Metab."},{"key":"ref_118","unstructured":"(2024, April 21). A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients with Pre-T2D or T2D and NAFLD\/NASH. Clinicaltrials.gov, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03970031."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Akbari, R., Behdarvand, T., Afarin, R., Yaghooti, H., Jalali, M.T., and Mohammadtaghvaei, N. (2021). Saroglitazar Improved Hepatic Steatosis and Fibrosis by Modulating Inflammatory Cytokines and Adiponectin in an Animal Model of Non-Alcoholic Steatohepatitis. BMC Pharmacol. Toxicol., 22.","DOI":"10.1186\/s40360-021-00524-8"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"9330","DOI":"10.1038\/s41598-020-66458-z","article-title":"The PPAR \u03b1\/\u03b3 Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease","volume":"10","author":"Kumar","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"21117","DOI":"10.1038\/s41598-020-78342-x","article-title":"Saroglitazar in Patients with Non-Alcoholic Fatty Liver Disease and Diabetic Dyslipidemia: A Prospective, Observational, Real World Study","volume":"10","author":"Goyal","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_122","unstructured":"(2024, April 21). A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor followed by an Active Treatment Extension in Adult Patients with (NASH) and Fibrosis Stages F2 and F3 (NATiV3). Clinicaltrials.gov, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04849728."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"630","DOI":"10.3390\/endocrines4030045","article-title":"Exploring SGLT-2 Inhibitors: Benefits beyond the Glucose-Lowering Effect\u2014What Is New in 2023?","volume":"4","author":"Young","year":"2023","journal-title":"Endocrines"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.mito.2021.06.008","article-title":"Chronic Treatment with Dapagliflozin Protects against Mitochondrial Dysfunction in the Liver of C57BL\/6NCrl Mice with High-Fat Diet\/Streptozotocin-Induced Diabetes Mellitus","volume":"59","author":"Belosludtsev","year":"2021","journal-title":"Mitochondrion"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/toxres\/tfad007","article-title":"Empagliflozin Attenuates Doxorubicin-Induced Cardiotoxicity by Activating AMPK\/SIRT-1\/PGC-1\u03b1-Mediated Mitochondrial Biogenesis","volume":"12","author":"Chen","year":"2023","journal-title":"Toxicol. Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e173675","DOI":"10.1172\/jci.insight.173675","article-title":"Transient Inhibition of Sodium-Glucose Cotransporter 2 after Ischemia\/Reperfusion Injury Ameliorates Chronic Kidney Disease","volume":"9","author":"Correa","year":"2024","journal-title":"JCI Insight"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/biof.1998","article-title":"Dapagliflozin Improves Diabetic Cognitive Impairment via Indirectly Modulating the Mitochondria Homeostasis of Hippocampus in Diabetic Mice","volume":"50","author":"Gui","year":"2024","journal-title":"Biofactors"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"175531","DOI":"10.1016\/j.ejphar.2023.175531","article-title":"Empagliflozin Ameliorates Cardiac Dysfunction in Heart Failure Mice via Regulating Mitochondrial Dynamics","volume":"942","author":"Lyu","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2022\/1197061","article-title":"Empagliflozin Enhances Autophagy, Mitochondrial Biogenesis, and Antioxidant Defense and Ameliorates Renal Ischemia\/Reperfusion in Nondiabetic Rats","volume":"2022","author":"Ala","year":"2022","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Dabravolski, S.A., Zhuravlev, A.D., Kartuesov, A.G., Borisov, E.E., Sukhorukov, V.N., and Orekhov, A.N. (2022). Mitochondria-Mediated Cardiovascular Benefits of Sodium-Glucose Co-Transporter 2 Inhibitors. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23105371"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Li, L., Li, Q., Huang, W., Han, Y., Tan, H., An, M., Xiang, Q., Zhou, R., Yang, L., and Cheng, Y. (2021). Dapagliflozin Alleviates Hepatic Steatosis by Restoring Autophagy via the AMPK-mTOR Pathway. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.589273"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Gager, G.M., von Lewinski, D., Sourij, H., Jilma, B., Eyileten, C., Filipiak, K., H\u00fclsmann, M., Kubica, J., Postula, M., and Siller-Matula, J.M. (2021). Effects of SGLT2 Inhibitors on Ion Homeostasis and Oxidative Stress Associated Mechanisms in Heart Failure. Biomed. Pharmacother., 143.","DOI":"10.1016\/j.biopha.2021.112169"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Koizumi, T., Watanabe, M., Yokota, T., Tsuda, M., Handa, H., Koya, J., Nishino, K., Tatsuta, D., Natsui, H., and Kadosaka, T. (2023). Empagliflozin Suppresses Mitochondrial Reactive Oxygen Species Generation and Mitigates the Inducibility of Atrial Fibrillation in Diabetic Rats. Front. Cardiovasc. Med., 10.","DOI":"10.3389\/fcvm.2023.1005408"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s10517-021-05277-2","article-title":"Effect of Dapagliflozin on the Functioning of Rat Liver Mitochondria In Vitro","volume":"171","author":"Belosludtseva","year":"2021","journal-title":"Bull. Exp. Biol. Med."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Morishita, A., Tadokoro, T., Fujihara, S., Iwama, H., Oura, K., Fujita, K., Tani, J., Takuma, K., Nakahara, M., and Shi, T. (2022). Ipragliflozin Attenuates Non-Alcoholic Steatohepatitis Development in an Animal Model. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0261310"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"350","DOI":"10.4254\/wjh.v12.i7.350","article-title":"Ipragliflozin-Induced Improvement of Liver Steatosis in Obese Mice May Involve Sirtuin Signaling","volume":"12","author":"Suga","year":"2020","journal-title":"World J. Hepatol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jamainternmed.2023.8029","article-title":"Outcomes of Various Classes of Oral Antidiabetic Drugs on Nonalcoholic Fatty Liver Disease","volume":"184","author":"Jang","year":"2024","journal-title":"JAMA Intern. Med."},{"key":"ref_139","unstructured":"(2024, April 23). Inventiva Announces Positive Results from the Phase II, LEGEND, Proof-of-Concept Study Combining Lanifibranor with Empagliflozin in Patients with MASH\/NASH and T2D. BioSpace. Available online: https:\/\/www.biospace.com\/article\/releases\/inventiva-announces-positive-results-from-the-phase-ii-legend-proof-of-concept-study-combining-lanifibranor-with-empagliflozin-in-patients-with-mash-nash-and-t2d\/."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"155612","DOI":"10.1016\/j.metabol.2023.155612","article-title":"Increased Expression of Sodium-Glucose Cotransporter 2 and O-GlcNAcylation in Hepatocytes Drives Non-Alcoholic Steatohepatitis","volume":"145","author":"Chun","year":"2023","journal-title":"Metabolism"},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Cheung, K.S., Ng, H.Y., Hui, R.W.H., Lam, L.K., Mak, L.Y., Ho, Y.C., Tan, J.T., Chan, E.W., Seto, W.K., and Yuen, M.F. (2024). Effects of Empagliflozin on Liver Fat in Metabolic-Dysfunction Associated Steatotic Liver Disease Patients without Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled Trial. Hepatology.","DOI":"10.1097\/HEP.0000000000000855"},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Perazza, F., Leoni, L., Colosimo, S., Musio, A., Bocedi, G., D\u2019Avino, M., Agnelli, G., Nicastri, A., Rossetti, C., and Sacilotto, F. (2024). Metformin and the Liver: Unlocking the Full Therapeutic Potential. Metabolites, 14.","DOI":"10.3390\/metabo14040186"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3390\/kinasesphosphatases1030012","article-title":"From Kinases to Diseases: Investigating the Role of AMPK in Human Pathologies","volume":"1","author":"Rey","year":"2023","journal-title":"Kinases Phosphatases"},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Vial, G., Detaille, D., and Guigas, B. (2019). Role of Mitochondria in the Mechanism(s) of Action of Metformin. Front. Endocrinol., 10.","DOI":"10.3389\/fendo.2019.00294"},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Geng, Y., Hern\u00e1ndez Villanueva, A., Oun, A., Buist-Homan, M., Blokzijl, H., Faber, K.N., Dolga, A., and Moshage, H. (2020). Protective Effect of Metformin against Palmitate-Induced Hepatic Cell Death. Biochim. Biophys. Acta Mol. Basis Dis., 1866.","DOI":"10.1016\/j.bbadis.2019.165621"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nature13270","article-title":"Metformin Suppresses Gluconeogenesis by Inhibiting Mitochondrial Glycerophosphate Dehydrogenase","volume":"510","author":"Madiraju","year":"2014","journal-title":"Nature"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"e2122287119","DOI":"10.1073\/pnas.2122287119","article-title":"Metformin, Phenformin, and Galegine Inhibit Complex IV Activity and Reduce Glycerol-Derived Gluconeogenesis","volume":"119","author":"LaMoia","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"de Mara\u00f1\u00f3n, A.M., D\u00edaz-Pozo, P., Canet, F., D\u00edaz-Morales, N., Abad-Jim\u00e9nez, Z., L\u00f3pez-Dom\u00e8nech, S., Vezza, T., Apostolova, N., Morillas, C., and Rocha, M. (2022). Metformin Modulates Mitochondrial Function and Mitophagy in Peripheral Blood Mononuclear Cells from Type 2 Diabetic Patients. Redox Biol., 53.","DOI":"10.1016\/j.redox.2022.102342"},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Xu, J., Kitada, M., and Koya, D. (2020). The Impact of Mitochondrial Quality Control by Sirtuins on the Treatment of Type 2 Diabetes and Diabetic Kidney Disease. Biochim. Biophys. Acta Mol. Basis Dis., 1866.","DOI":"10.1016\/j.bbadis.2020.165756"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12944-021-01461-5","article-title":"Elucidation of SIRT-1\/PGC-1\u03b1-Associated Mitochondrial Dysfunction and Autophagy in Nonalcoholic Fatty Liver Disease","volume":"20","author":"Jiang","year":"2021","journal-title":"Lipids Health Dis."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Meng, H., Yan, W.-Y., Lei, Y.-H., Wan, Z., Hou, Y.-Y., Sun, L.-K., and Zhou, J.-P. (2019). SIRT3 Regulation of Mitochondrial Quality Control in Neurodegenerative Diseases. Front. Aging Neurosci., 11.","DOI":"10.3389\/fnagi.2019.00313"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00018-023-05093-z","article-title":"SIRT3\/6: An Amazing Challenge and Opportunity in the Fight against Fibrosis and Aging","volume":"81","author":"Wei","year":"2024","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"5521","DOI":"10.1038\/s41598-024-55923-8","article-title":"Emerging Roles of SIRT1 Activator, SRT2104, in Disease Treatment","volume":"14","author":"Chang","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1021\/acs.jmedchem.3c01979","article-title":"SIRT3 Activation a Promise in Drug Development? New Insights into SIRT3 Biology and Its Implications on the Drug Discovery Process","volume":"67","author":"Lambona","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.tem.2022.10.004","article-title":"SIRT6: Therapeutic Target for Nonalcoholic Fatty Liver Disease","volume":"33","author":"Zang","year":"2022","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Dabravolski, S.A., Bezsonov, E.E., Baig, M.S., Popkova, T.V., Nedosugova, L.V., Starodubova, A.V., and Orekhov, A.N. (2021). Mitochondrial Mutations and Genetic Factors Determining NAFLD Risk. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094459"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/brain\/awac421","article-title":"Randomized Trial of Bilateral Gene Therapy Injection for m.11778G>A MT-ND4 Leber Optic Neuropathy","volume":"146","author":"Newman","year":"2023","journal-title":"Brain"}],"container-title":["Antioxidants"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3921\/13\/8\/906\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:24:21Z","timestamp":1760109861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3921\/13\/8\/906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,26]]},"references-count":157,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["antiox13080906"],"URL":"https:\/\/doi.org\/10.3390\/antiox13080906","relation":{},"ISSN":["2076-3921"],"issn-type":[{"value":"2076-3921","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,26]]}}}